SUPPLEMENTAL DATA LIST
Supplemental Figure 1. scRNA-seq quality control.

Supplemental Figure 2. Individual patient UMAP plots and cell cycle analysis.

Supplemental Figure 3. Proportion of monocyte clusters in sepsis only and sepsis+ARDS patients.

Supplemental Figure 4. Expression of SOCS1 and IFN receptors in the monocyte clusters.

Supplemental Table 1. Cell count for each cell cluster stratified by sample.

Supplemental Table 2. Marker genes used for each cell cluster.

Supplemental Table 3. Differential gene expression in all cells.

Supplemental Table 4. ClueGO pathway enrichment associated with downregulated genes in NK cells.

Supplemental Table 5. ClueGO pathway enrichment associated with up-regulated genes in each monocyte subpopulation.

Supplemental Table 6. Differential expression of the 29 genes used for bulk data validation in monocytes from scRNA-seq analysis.

Supplemental Table 7. Description of datasets used for score generation.

Supplemental Table 8. Reagents and materials.

A
nCount_RNA



Supplemental Figure 1. scRNA-seq quality control. Violin plots of (A) total UMI count, (B) numbers of unique genes identified, and (C) proportion of mitochondrial genes in each cell cluster.


Supplemental Figure 2. Individual patient UMAP plots. Low dimension UMAP plot of PBMC by (a) group and (b) individual patients.


Supplemental Figure 3. Proportion of monocyte clusters in sepsis only and sepsis+ARDS patients. The proportion of each color-coded monocyte cluster in sepsis only and sepsis+ARDS patients is shown in the pie charts.

A


B

IFNGR1


IFNAR1


Supplemental Figure 4. Expression of SOCS1 and IFN receptors in the monocyte clusters. Violin plots showing (a) SOCS1, (b) IFNGR1, and (c) IFNAR1 expression in each monocyte cluster in sepsis only and sepsis+ARDS patients.

Supplemental Table 1. Cell count for each cell cluster stratified by sample

|  | Sepsis1 | Sepsis2 | Sepsis3 | Sepsis4 | ARDS1 | ARDS2 | ARDS3 |
| :--- | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Mk | 66 | 44 | 211 | 37 | 73 | 56 | 49 |
| Mono/B | 24 | 35 | 14 | 24 | 23 | 15 | 8 |
| CD4T-3 | 187 | 69 | 252 | 119 | 245 | 228 | 45 |
| CD4T-2 | 396 | 231 | 415 | 232 | 360 | 415 | 134 |
| CD4T-1 | 611 | 208 | 693 | 268 | 339 | 652 | 349 |
| CD8T | 560 | 346 | 538 | 125 | 423 | 156 | 129 |
| NKT | 103 | 192 | 290 | 25 | 379 | 12 | 99 |
| NK | 537 | 242 | 244 | 163 | 198 | 54 | 119 |
| B | 421 | 19 | 252 | 295 | 594 | 359 | 135 |
| Mono/T | 82 | 21 | 89 | 14 | 36 | 19 | 42 |
| CD14Mono-4 | 236 | 259 | 219 | 338 | 276 | 361 | 148 |
| CD14Mono-3 | 258 | 366 | 156 | 539 | 296 | 422 | 281 |
| CD14Mono-2 | 171 | 629 | 125 | 654 | 282 | 329 | 161 |
| CD14Mono-1 | 178 | 554 | 203 | 888 | 369 | 393 | 237 |
| CD16Mono | 113 | 136 | 151 | 239 | 225 | 80 | 95 |
|  |  |  |  |  |  |  |  |
| SUM | 3943 | 3351 | 3852 | 3960 | 4118 | 3551 | 2031 |

Supplemental Table 2. Marker genes used for each cell cluster

| \# Top 10 marker genes for each cluster |  |  |  |  |  |  |  |  |  |  |
| :--- | :--- | :--- | :--- | :--- | :--- | :--- | :--- | :--- | :--- | :--- |
| CD14Mono-1 | S100A9 | S100A8 | S100A12 | LYZ | LGALS1 | TSPO | CTSD | S100A6 | CSTA |  |
| CD14Mono-2 | TIMP1 | G0S2 | CST3 | TYROBP | AIF1 | CTSS | THBS1 | FCN1 | SNHG15 | MAP3K8 |
| CD14Mono-3 | S100A8 | S100A12 | NAMPT | RETN | CTSD | S100P | LGALS1 | BCL2A1 | GLUL |  |
| CD14Mono-4 | PPBP | GNG11 | MAP3K8 | SLC25A37 | THBS1 | HIF1A | G0S2 | CLEC7A | SOD2 |  |
| CD8T | CMC1 | DUSP2 | GZMK | CCL5 | CD8A | CD3D | JUN | APOBEC3G | CD3E | TRBC2 |
| CD4T-1* | CCR7 | PIK3IP1 | LEPROTL1 | RPS6 | SARAF | SOCS3 | RPS12 | IL7R | RPLP0 | RPSA |
| CD4T-3 | RPS6 | SARAF | LEPROTL1 | CCR7 | CD6 | IL7R | PIK3IP1 | LTB | SPOCK2 | ZFP36L2 |
| B | HLA-DQB1 | CD79A | CD74 | IGKC | HLA-DRA | IGLC2 | HLA-DPB1 | IGHM | HLA-DRB1 | IGHA1 |
| NK | GNLY | NKG7 | GZMB | CCL3 | FGFBP2 | CTSW | KLRB1 | SPON2 | CD7 | CCL4 |
| NKT | GZMH | GNLY | NKG7 | CCL5 | CCL4 | FGFBP2 | CST7 | CMC1 | GZMA | KLRB1 |
| CD16Mono | IFITM2 | IFITM3 | LILRA1 | LST1 | COTL1 | C10orf54 | RHOC | IRF7 | PSAP | CD68 |
| Mk | PF4 | PPBP | GNG11 | GP9 | ITGA2B | SDPR | HIST1H2AC | RGS18 | TSC22D1 | ACRBP |
| Mono/T | MT-CO2 | MT-CO3 | MT-ATP6 | MT-ND1 | TSPYL2 | AC016831.7 | SPOCK2 | RP11-138A9.1 | KLF6 | TRAC |
| Mono/B | HLA-DPA1 | HLA-DPB1 | CD74 | HLA-DRA | HLA-DMA | HLA-DRB1 | HLA-DQA1 | HLA-DQB1 | AREG | PTGDS |

*the marker genes for CD4T-2 cluster show the same list as CD4T-1 in global differentiation.

Supplemental Table 3. Differential gene expression in all cells

| Gene | avg_logFC | Sepsis only \% | Sepsis+ARDS\% | p_val_mast | p_val_adj_mast |
| :---: | :---: | :---: | :---: | :---: | :---: |
| IGLC2 | 0.685 | 0.384 | 0.278 | 4.35E-68 | 8.70E-65 |
| CD79A | 0.293 | 0.598 | 0.552 | $1.00 \mathrm{E}-43$ | $2.00 \mathrm{E}-40$ |
| HLA-DQB1 | 0.260 | 0.914 | 0.665 | $0.00 \mathrm{E}+00$ | $0.00 \mathrm{E}+00$ |
| IGHA1 | 0.250 | 0.795 | 0.583 | 1.52E-270 | 3.03E-267 |
| CD74 | 0.224 | 0.864 | 0.759 | $1.31 \mathrm{E}-98$ | 2.62E-95 |
| HLA-DRA | 0.212 | 0.844 | 0.726 | 1.81E-109 | 3.63E-106 |
| HLA-DPB1 | 0.199 | 0.833 | 0.69 | 2.59E-148 | $5.18 \mathrm{E}-145$ |
| IGHM | 0.167 | 0.439 | 0.476 | $1.67 \mathrm{E}-66$ | 3.33E-63 |
| MS4A1 | 0.161 | 0.546 | 0.506 | $1.09 \mathrm{E}-39$ | 2.18E-36 |
| EZR | 0.159 | 0.832 | 0.763 | $2.24 \mathrm{E}-43$ | $4.47 \mathrm{E}-40$ |
| HLA-DRB1 | 0.153 | 0.805 | 0.665 | $8.97 \mathrm{E}-142$ | $1.79 \mathrm{E}-138$ |
| IGLC3 | 0.151 | 0.337 | 0.21 | $2.00 \mathrm{E}-106$ | $4.00 \mathrm{E}-103$ |
| KLF2 | 0.127 | 0.754 | 0.648 | $3.58 \mathrm{E}-70$ | 7.17E-67 |
| IFNGR2 | 0.126 | 0.73 | 0.641 | $4.60 \mathrm{E}-52$ | 9.20E-49 |
| NAMPT | 0.121 | 0.922 | 0.791 | $2.31 \mathrm{E}-223$ | 4.63E-220 |
| IFI44L | 0.120 | 0.418 | 0.36 | $0.00 \mathrm{E}+00$ | $0.00 \mathrm{E}+00$ |
| LTB | 0.118 | 0.749 | 0.681 | $1.23 \mathrm{E}-39$ | 2.45E-36 |
| CD83 | 0.114 | 0.89 | 0.726 | 1.41E-229 | 2.82E-226 |
| TSC22D3 | 0.112 | 0.975 | 0.928 | 6.13E-64 | $1.23 \mathrm{E}-60$ |
| TNFRSF13C | 0.111 | 0.728 | 0.627 | 8.16E-74 | $1.63 \mathrm{E}-70$ |
| CXCR4 | 0.110 | 0.98 | 0.942 | $1.24 \mathrm{E}-51$ | $2.47 \mathrm{E}-48$ |
| RGS2 | 0.109 | 0.766 | 0.692 | $1.77 \mathrm{E}-39$ | $3.54 \mathrm{E}-36$ |
| GLUL | 0.108 | 0.799 | 0.681 | $1.60 \mathrm{E}-121$ | 3.21E-118 |
| HLA-DPA1 | 0.107 | 0.76 | 0.629 | $1.49 \mathrm{E}-111$ | $2.98 \mathrm{E}-108$ |
| VNN2 | 0.104 | 0.441 | 0.463 | 5.55E-13 | $1.11 \mathrm{E}-09$ |
| ATP6V0B | 0.102 | 0.738 | 0.641 | $1.25 \mathrm{E}-90$ | 2.50E-87 |
| MAFF | -0.101 | 0.931 | 0.696 | 0.00E+00 | $0.00 \mathrm{E}+00$ |
| TMSB4X | -0.102 | 0.999 | 0.998 | $4.44 \mathrm{E}-28$ | 8.88E-25 |
| XCL2 | -0.110 | 0.882 | 0.748 | 2.16E-169 | 4.33E-166 |
| CD7 | -0.111 | 0.8 | 0.716 | $1.64 \mathrm{E}-81$ | 3.27E-78 |
| PPBP | -0.118 | 0.799 | 0.678 | 1.19E-107 | 2.39E-104 |
| RGS18 | -0.119 | 0.725 | 0.642 | $8.84 \mathrm{E}-45$ | $1.77 \mathrm{E}-41$ |
| GP9 | -0.121 | 0.583 | 0.516 | $1.19 \mathrm{E}-26$ | $2.38 \mathrm{E}-23$ |
| GZMH | -0.122 | 0.81 | 0.678 | 3.30E-156 | 6.60E-153 |
| PF4 | -0.127 | 0.862 | 0.687 | $1.44 \mathrm{E}-247$ | $2.89 \mathrm{E}-244$ |
| CCL5 | -0.131 | 0.894 | 0.782 | 8.82E-169 | 1.76E-165 |
| AREG | -0.132 | 0.937 | 0.673 | $0.00 \mathrm{E}+00$ | 0.00E+00 |
| KLRD1 | -0.135 | 0.75 | 0.619 | $3.34 \mathrm{E}-130$ | $6.67 \mathrm{E}-127$ |
| GZMA | -0.140 | 0.731 | 0.645 | 3.22E-67 | $6.44 \mathrm{E}-64$ |
| MT2A | -0.145 | 0.906 | 0.86 | 8.69E-77 | $1.74 \mathrm{E}-73$ |
| CST7 | -0.170 | 0.822 | 0.729 | $2.45 \mathrm{E}-105$ | 4.91E-102 |
| GZMB | -0.173 | 0.731 | 0.661 | $1.25 \mathrm{E}-51$ | $2.49 \mathrm{E}-48$ |
| CCL4 | -0.189 | 0.884 | 0.732 | $6.85 \mathrm{E}-230$ | 1.37E-226 |
| KLRB1 | -0.200 | 0.764 | 0.68 | $4.36 \mathrm{E}-64$ | $8.73 \mathrm{E}-61$ |
| SPON2 | -0.201 | 0.874 | 0.696 | 7.01E-292 | $1.40 \mathrm{E}-288$ |
| CTSW | -0.209 | 0.514 | 0.466 | 8.62E-38 | 1.72E-34 |
| CMC1 | -0.238 | 0.774 | 0.657 | 5.17E-126 | $1.03 \mathrm{E}-122$ |
| DUSP2 | -0.238 | 0.908 | 0.778 | 1.75E-223 | 3.50E-220 |
| FGFBP2 | -0.249 | 0.859 | 0.695 | $1.33 \mathrm{E}-257$ | $2.66 \mathrm{E}-254$ |
| NKG7 | -0.274 | 0.875 | 0.778 | $4.55 \mathrm{E}-155$ | 9.11E-152 |
| PTGDS | -0.283 | 0.761 | 0.629 | $4.74 \mathrm{E}-127$ | $9.47 \mathrm{E}-124$ |
| CCL3 | -0.326 | 0.908 | 0.735 | 8.92E-297 | $1.78 \mathrm{E}-293$ |
| GNLY | -0.347 | 0.817 | 0.767 | 3.15E-51 | $6.31 \mathrm{E}-48$ |

Supplemental Table 4. ClueGO pathway enrichment associated with down-regulated genes in NK cells

| GOID | GOTerm | Term PValue | Term PValue Corrected with Bonferroni step down | Group PValue | Group PValue Corrected with Bonferroni step down | GOGroups | Associated Genes Found |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| $\begin{aligned} & \hline \text { GO:00 } \\ & 02576 \\ & \hline \end{aligned}$ | platelet degranulation | 3.56E-05 | 3.31E-03 | 3.56E-05 | $2.14 \mathrm{E}-04$ | Group00 | [APLP2, CD63, GSTP1, IER3, PSAP, TIMP1, TUBA4A] |
| $\begin{aligned} & \hline \text { GO:00 } \\ & 43124 \end{aligned}$ | negative regulation of I-kappaB kinase/NF-kappaB signaling | 5.07E-05 | $4.61 \mathrm{E}-03$ | 5.07E-05 | 2.03E-04 | Group01 | [BIRC3, GSTP1, RHOA, RIOK3, TNFAIP3] |
| $\begin{aligned} & \text { GO:00 } \\ & 46632 \end{aligned}$ | alpha-beta T cell differentiation | 4.28E-05 | 3.94E-03 | 4.28E-05 | 2.14E-04 | Group02 | [NFKBIZ, PRDM1, PTGER4, RHOA, TCF7, ZNF683] |
| $\begin{aligned} & \hline \text { GO:00 } \\ & 08347 \\ & \hline \end{aligned}$ | glial cell migration | 1.99E-06 | $2.01 \mathrm{E}-04$ | 1.99E-06 | 1.60E-05 | Group03 | [BIRC3, CCL3, CCL4, GPX4, IDH2, TSPO] |
| $\begin{aligned} & \hline \text { GO:00 } \\ & 10951 \\ & \hline \end{aligned}$ | negative regulation of endopeptidase activity | 8.93E-06 | 8.93E-04 | 8.93E-06 | 6.25E-05 | Group04 | [APLP2, BIN1, BIRC3, CST7, GSTP1, HERPUD1, SERPINB1, SPOCK2, TIMP1, TNFRSF1B] |
| $\begin{aligned} & \hline \text { GO:00 } \\ & 31663 \\ & \hline \end{aligned}$ | lipopolysaccharide-mediated signaling pathway | 7.34E-05 | 6.31E-03 | 7.34E-05 | 2.20E-04 | Group05 | [CCL3, CCL4, NFKBIA, PRDM1, TNFAIP3] |
| $\begin{aligned} & \text { GO:00 } \\ & 43407 \end{aligned}$ | negative regulation of MAP kinase activity | $2.61 \mathrm{E}-05$ | 2.48E-03 | 9.63E-05 | 9.63E-05 | Group06 | [BIRC3, DUSP1, DUSP2, GSTP1, KLF6, RGS2] |
| $\begin{aligned} & \text { GO:00 } \\ & 71901 \\ & \hline \end{aligned}$ | negative regulation of protein serine/threonine kinase activity | 9.63E-05 | 7.99E-03 | 9.63E-05 | $9.63 \mathrm{E}-05$ | Group06 | [BIRC3, DUSP1, DUSP2, GSTP1, KLF6, RGS2, TNFAIP3] |
| $\begin{aligned} & \hline \text { GO:00 } \\ & 71216 \\ & \hline \end{aligned}$ | cellular response to biotic stimulus | 1.50E-10 | 1.59E-08 | 8.36E-12 | 8.36E-11 | Group07 | [BIRC3, CCL3, CCL4, CEBPB, GSTP1, HSPA5, IRF8, NFKBIA, PRDM1, RHOA, TNFAIP3, TNFRSF1B, TSPO, ZFP36] |
| $\begin{aligned} & \text { GO:00 } \\ & 02237 \\ & \hline \end{aligned}$ | response to molecule of bacterial origin | 3.58E-11 | 3.83E-09 | 8.36E-12 | 8.36E-11 | Group07 | [BIRC3, CCL3, CCL4, CEBPB, FOS, GSTP1, IRF8, JUN, JUNB, NFKBIA, PRDM1, PTGER4, RHOA, TIMP1, TNFAIP3, TNFRSF1B, TSPO, ZFP36] |
| $\begin{aligned} & \mathrm{GO}: 00 \\ & 32496 \\ & \hline \end{aligned}$ | response to lipopolysaccharide | 1.60E-11 | 1.73E-09 | 8.36E-12 | 8.36E-11 | Group07 | [BIRC3, CCL3, CCL4, CEBPB, FOS, GSTP1, IRF8, JUN, JUNB, NFKBIA, PRDM1, PTGER4, RHOA, TIMP1, TNFAIP3, TNFRSF1B, TSPO, ZFP36] |
| $\begin{aligned} & \text { GO:00 } \\ & 71219 \end{aligned}$ | cellular response to molecule of bacterial origin | 6.18E-10 | 6.43E-08 | 8.36E-12 | 8.36E-11 | Group07 | [BIRC3, CCL3, CCL4, CEBPB, GSTP1, IRF8, NFKBIA, PRDM1, RHOA, TNFAIP3, TNFRSF1B, TSPO, ZFP36] |
| $\begin{aligned} & \text { GO:00 } \\ & 71222 \\ & \hline \end{aligned}$ | cellular response to lipopolysaccharide | 3.16E-10 | 3.32E-08 | 8.36E-12 | 8.36E-11 | Group07 | [BIRC3, CCL3, CCL4, CEBPB, GSTP1, IRF8, NFKBIA, PRDM1, RHOA, TNFAIP3, TNFRSF1B, TSPO, ZFP36] |
| $\begin{aligned} & \mathrm{GO}: 00 \\ & 46683 \\ & \hline \end{aligned}$ | response to organophosphorus | $6.30 \mathrm{E}-05$ | 5.61E-03 | 9.24E-05 | 1.85E-04 | Group08 | [DUSP1, FOS, HSP90B1, HSPA5, JUN, JUNB, ZFP36L1] |
| $\begin{aligned} & \text { GO:00 } \\ & 71241 \\ & \hline \end{aligned}$ | cellular response to inorganic substance | 8.14E-05 | $6.92 \mathrm{E}-03$ | 9.24E-05 | 1.85E-04 | Group08 | [ALOX5AP, FOS, HSPA5, JUN, JUNB, MT2A, RHOA, TSPO] |
| $\begin{aligned} & \text { GO:00 } \\ & 14074 \end{aligned}$ | response to purine-containing compound | 1.16E-04 | 9.39E-03 | 9.24E-05 | 1.85E-04 | Group08 | [DUSP1, FOS, HSP90B1, HSPA5, JUN, JUNB, ZFP36L1] |
| $\begin{aligned} & \text { GO:00 } \\ & 51591 \\ & \hline \end{aligned}$ | response to cAMP | 7.01E-05 | 6.17E-03 | 9.24E-05 | 1.85E-04 | Group08 | [DUSP1, FOS, HSPA5, JUN, JUNB, ZFP36L1] |
| $\begin{aligned} & \text { GO:00 } \\ & 51592 \\ & \hline \end{aligned}$ | response to calcium ion | 5.88E-05 | 5.30E-03 | 9.24E-05 | 1.85E-04 | Group08 | [ALOX5AP, DUSP1, FOS, HSPA5, JUN, JUNB, RHOA] |
| $\begin{aligned} & \text { GO:00 } \\ & 71248 \end{aligned}$ | cellular response to metal ion | 2.96E-05 | $2.78 \mathrm{E}-03$ | 9.24E-05 | 1.85E-04 | Group08 | [ALOX5AP, FOS, HSPA5, JUN, JUNB, MT2A, RHOA, TSPO] |
| $\begin{aligned} & \hline \text { GO:00 } \\ & 71277 \\ & \hline \end{aligned}$ | cellular response to calcium ion | 1.50E-05 | 1.47E-03 | 9.24E-05 | 1.85E-04 | Group08 | [ALOX5AP, FOS, HSPA5, JUN, JUNB, RHOA] |
| $\begin{aligned} & \text { GO:00 } \\ & 43900 \\ & \hline \end{aligned}$ | regulation of multi-organism process | $3.24 \mathrm{E}-08$ | 3.30E-06 | 6.35E-08 | 5.71E-07 | Group09 | [BIRC3, CCL3, CCL4, IFITM1, IRF8, JUN, PFN1, PRDM1, PRF1, PTGDS, RIOK3, SNX3, TIMP1, TNFAIP3, ZFP36] |
| $\begin{aligned} & \text { GO:00 } \\ & 43901 \\ & \hline \end{aligned}$ | negative regulation of multi-organism process | 1.21E-09 | 1.24E-07 | 6.35E-08 | 5.71E-07 | Group09 | [CCL3, CCL4, IFITM1, IRF8, JUN, PRDM1, PTGDS, RIOK3, SNX3, TIMP1, TNFAIP3, ZFP36] |
| $\begin{aligned} & \mathrm{GO}: 00 \\ & 43903 \\ & \hline \end{aligned}$ | regulation of symbiosis, encompassing mutualism through parasitism | 7.11E-05 | 6.19E-03 | 6.35E-08 | 5.71E-07 | Group09 | [CCL3, CCL4, IFITM1, IRF8, JUN, PFN1, SNX3, ZFP36] |
| $\begin{aligned} & \text { GO:00 } \\ & 48525 \end{aligned}$ | negative regulation of viral process | 2.61E-05 | $2.48 \mathrm{E}-03$ | 6.35E-08 | 5.71E-07 | Group09 | [CCL3, CCL4, IFITM1, JUN, SNX3, ZFP36] |
| $\begin{aligned} & \text { GO:00 } \\ & 19080 \end{aligned}$ | viral gene expression | 8.73E-05 | 7.34E-03 | 6.35E-08 | 5.71E-07 | Group09 | [CCL3, CCL4, JUN, PFN1, ZFP36] |
| $\begin{aligned} & \text { GO:00 } \\ & 19083 \end{aligned}$ | viral transcription | 1.85E-05 | 1.80E-03 | 6.35E-08 | 5.71E-07 | Group09 | [CCL3, CCL4, JUN, PFN1, ZFP36] |
| $\begin{aligned} & \text { GO:00 } \\ & 32897 \\ & \hline \end{aligned}$ | negative regulation of viral transcription | $2.17 \mathrm{E}-05$ | 2.08E-03 | 6.35E-08 | 5.71E-07 | Group09 | [CCL3, CCL4, JUN, ZFP36] |
| $\begin{aligned} & \text { GO:00 } \\ & 46782 \\ & \hline \end{aligned}$ | regulation of viral transcription | 1.33E-05 | 1.31E-03 | 6.35E-08 | 5.71E-07 | Group09 | [CCL3, CCL4, JUN, PFN1, ZFP36] |
| $\begin{aligned} & \text { GO:00 } \\ & 43922 \\ & \hline \end{aligned}$ | negative regulation by host of viral transcription | 1.14E-04 | 9.37E-03 | 6.35E-08 | 5.71E-07 | Group09 | [CCL3, CCL4, JUN] |

Supplemental Table 5. Enriched pathways and up-regulated genes in each monocyte subpopulation

| GOID | GOTerm | Term PValue | Term PValue Corrected with Bonferroni step down | Group PValue | Group PValue Corrected with Bonferroni step down | $\begin{aligned} & \text { GOGr } \\ & \text { oups } \end{aligned}$ | Associated Genes Found |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| CD14Mono-1 |  |  |  |  |  |  |  |
| GO:0051607 | defense response to virus | 4.85E-06 | 3.15E-04 | 4.85E-06 | 9.69E-06 | Group0 | [GBP1, IF144L, IFIT2, IFIT3, IFITM1, IRF7, RNASE2, SAMHD1, SEC14L1, UNC93B1] |
| 60:0034340 | response to type l interferon | $4.33 \mathrm{E}-05$ | $2.73 \mathrm{E}-03$ | $4.33 \mathrm{E}-05$ | 4.33E-05 | Group1 | [GBP2, IFIT2, IFIT3, IFITM1, IRF7, SAMHD1] |
| 60:0071357 | cellular response to type linterferon | 3.12E-05 | $2.00 \mathrm{E}-03$ | $4.33 \mathrm{E}-05$ | 4.33E-05 | Group1 | [GBP2, IFIT2, IFIT3, IFITM1, IRF7, SAMHD1] |
| GO:0060337 | type l interferon signaling pathway | 3.12E-05 | $2.00 \mathrm{E}-03$ | $4.33 \mathrm{E}-05$ | $4.33 \mathrm{E}-05$ | Group1 | [GBP2, IFIT2, IFIT3, IFITM1, IRF7, SAMHD1] |
| CD14Mono-2 |  |  |  |  |  |  |  |
| G0:0002576 | platelet degranulation | 2.66E-06 | 4.52E-05 | $2.66 \mathrm{E}-06$ | 2.13E-05 | Group0 | [ITGA2B, PECAM1, PLEK, PPBP, SERPING1, SPARC, VCL] |
| 60:0003229 | ventricular cardiac muscle tissue development | 2.74E-03 | $5.49 \mathrm{E}-03$ | 2.74E-03 | 5.49E-03 | Group1 | [HERPUD1, ID2, PPBP] |
| 60:0090502 | RNA phosphodiester bond hydrolysis, endonucleolytic | 5.25E-03 | $5.25 \mathrm{E}-03$ | 5.25E-03 | 5.25E-03 | Group2 | [RNASE1, RNASE2, RNASET2] |
| GO:0071295 | cellular response to vitamin | 8.35E-04 | $6.68 \mathrm{E}-03$ | 8.35E-04 | 3.34E-03 | Group3 | [ATP2B1, BACH1, PPBP] |
| 60:2000257 | regulation of protein activation cascade | 1.34E-03 | $5.36 \mathrm{E}-03$ | 1.34E-03 | 4.02E-03 | Group4 | [C1QB, C3AR1, IGKC, SERPING1] |
| 60:0030449 | regulation of complement activation | 1.23E-03 | 6.15E-03 | 1.34E-03 | 4.02E-03 | Group4 | [C1QB, C3AR1, IGKC, SERPING1] |
| 60:0034109 | homotypic cell-cell adhesion | 6.79E-04 | 6.79E-03 | $6.79 \mathrm{E}-04$ | $3.40 \mathrm{E}-03$ | Group5 | [HSPB1, ITGA2B, PLEK, VCL] |
| 60:0070527 | platelet aggregation | 1.66E-04 | $2.48 \mathrm{E}-03$ | 6.79E-04 | $3.40 \mathrm{E}-03$ | Group5 | [HSPB1, ITGA2B, PLEK, VCL] |
| 60:0034340 | response to type l interferon | 5.91E-04 | $7.09 \mathrm{E}-03$ | 5.91E-04 | 3.55E-03 | Group6 | [GBP2, IFIT2, IFIT3, ISG20] |
| 60:0071357 | cellular response to type l interferon | 4.74E-04 | $6.16 \mathrm{E}-03$ | $5.91 \mathrm{E}-04$ | 3.55E-03 | Group6 | [GBP2, IFIT2, IFIT3, ISG20] |
| 60:0060337 | type I interferon signaling pathway | 4.74E-04 | $6.16 \mathrm{E}-03$ | $5.91 \mathrm{E}-04$ | 3.55E-03 | Group6 | [GBP2, IFIT2, IFIT3, ISG20] |
| 60:1902622 | regulation of neutrophil migration | 1.04E-03 | $7.29 \mathrm{E}-03$ | $2.46 \mathrm{E}-04$ | 1.72E-03 | Group7 | [C3AR1, PPBP, RNASE1] |
| 60:1990266 | neutrophil migration | 1.48E-04 | $2.36 \mathrm{E}-03$ | $2.46 \mathrm{E}-04$ | 1.72E-03 | Group7 | [C3AR1, LGALS3, PECAM1, PPBP, RNASE1] |
| 60:0030593 | neutrophil chemotaxis | 1.06E-03 | $6.38 \mathrm{E}-03$ | $2.46 \mathrm{E}-04$ | 1.72E-03 | Group7 | [C3AR1, LGALS3, PPBP, RNASE1] |
| 60:0071622 | regulation of granulocyte chemotaxis | 1.69E-03 | $5.07 \mathrm{E}-03$ | $2.46 \mathrm{E}-04$ | 1.72E-03 | Group7 | [C3AR1, PPBP, RNASE1] |
| 60:1902624 | positive regulation of neutrophil migration | 6.99E-04 | $6.29 \mathrm{E}-03$ | $2.46 \mathrm{E}-04$ | 1.72E-03 | Group7 | [C3AR1, PPBP, RNASE1] |
| 60:0071624 | positive regulation of granulocyte chemotaxis | 6.17E-04 | $6.78 \mathrm{E}-03$ | $2.46 \mathrm{E}-04$ | 1.72E-03 | Group7 | [C3AR1, PPBP, RNASE1] |
| 60:0090022 | regulation of neutrophil chemotaxis | 6.99E-04 | 6.29E-03 | $2.46 \mathrm{E}-04$ | 1.72E-03 | Group7 | [C3AR1, PPBP, RNASE1] |
| 60:0090023 | positive regulation of neutrophil chemotaxis | 4.71E-04 | $6.60 \mathrm{E}-03$ | $2.46 \mathrm{E}-04$ | 1.72E-03 | Group7 | [C3AR1, PPBP, RNASE1] |
| CD14Mono-3 |  |  |  |  |  |  |  |
| 60:0061082 | myeloid leukocyte cytokine production | 7.55E-05 | $6.27 \mathrm{E}-03$ | 7.55E-05 | 1.51E-04 | Group0 | [BCL6, CD36, FCER1G, IRAK3] |
| G0:2000107 | negative regulation of leukocyte apoptotic process | $9.98 \mathrm{E}-05$ | $8.18 \mathrm{E}-03$ | $9.98 \mathrm{E}-05$ | $9.98 \mathrm{E}-05$ | Group1 | [BCL6, CCR7, FCER1G, IRF7, TSC22D3] |
| 60:0002526 | acute inflammatory response | $1.10 \mathrm{E}-05$ | $9.56 \mathrm{E}-04$ | 1.10E-05 | $5.50 \mathrm{E}-05$ | Group2 | [ALOX5AP, C5AR2, CAPG, CCR7, CD6, CFP, CSRP1, FCER1G, IGKC, TIMP1, TREM1] |
| 60:0002576 | platelet degranulation | $3.80 \mathrm{E}-10$ | $3.61 \mathrm{E}-08$ | $3.80 \mathrm{E}-10$ | 3.04E-09 | Group3 | [APLP2, APP, CD36, CD63, CFD, CFP, F13A1, FCER1G, PLEK, SPARC, TAGLN2, TIMP1, TUBA4A] |
| 60:0007229 | integrin-mediated signaling pathway | 5.74E-05 | $4.82 \mathrm{E}-03$ | 5.74E-05 | 1.72E-04 | Group4 | [BST1, CD63, FCER1G, ITGB1, ITGB7, PLEK, TIMP1] |
| 60:0009615 | response to virus | $2.26 \mathrm{E}-05$ | 1.94E-03 | $2.26 \mathrm{E}-05$ | 9.03E-05 | Group5 | [CXCR4, GBP1, IF144L, IFIT3, IFITM1, IFNGR2, IRAK3, IRF7, OASL, RNASE2, SEC14L1, UNC93B1] |
| 60:0051607 | defense response to virus | $2.86 \mathrm{E}-05$ | $2.43 \mathrm{E}-03$ | $2.26 \mathrm{E}-05$ | $9.03 \mathrm{E}-05$ | Group5 | [GBP1, IF144L, IFIT3, IFITM1, IFNGR2, IRF7, OASL, RNASE2, SEC14L1, UNC93B1] |
| 60:0002237 | response to molecule of bacterial origin | 7.56E-06 | 6.66E-04 | $7.56 \mathrm{E}-06$ | 4.54E-05 | Group6 | [AKIRIN2, CCR7, CD36, CD6, CSF2RB, IRAK3, JUNB, MGST1, NFKBIA, PTGER2, SPARC, TIMP1, TNFRSF1B, ZFP36] |
| GO:0032496 | response to lipopolysaccharide | 4.32E-06 | 3.85E-04 | $7.56 \mathrm{E}-06$ | $4.54 \mathrm{E}-05$ | Group6 | [AKIRIN2, CCR7, CD36, CD6, CSF2RB, IRAK3, JUNB, MGST1, NFKBIA, PTGER2, SPARC, TIMP1, TNFRSF1B, ZFP36] |
| GO:0036230 | granulocyte activation | $2.31 \mathrm{E}-08$ | 2.10E-06 | 3.28E-08 | $2.30 \mathrm{E}-07$ | Group7 | [BST1, CD36, CD63, CD68, CD93, CFD, CFP, CKAP4, FCER1G, FGL2, FPR2, GLIPR1, GNS, LAMTOR2, LTA4H, MGST1, QPCT, RNASE2, |
| G0:0002446 | neutrophil mediated immunity | $2.37 \mathrm{E}-08$ | $2.13 \mathrm{E}-06$ | 3.28E-08 | $2.30 \mathrm{E}-07$ | Group7 | [BST1, CD36, CD63, CD68, CD93, CFD, CFP, CKAP4, FCER1G, FGL2, FPR2, GLIPR1, GNS, LAMTOR2, LTA4H, MGST1, QPCT, RNASE2, SELL. TIMP1, TNFRSF1B] |
| GO:0042119 | neutrophil activation | 1.93E-08 | 1.78E-06 | 3.28E-08 | $2.30 \mathrm{E}-07$ | Group7 | [BST1, CD36, CD63, CD68, CD93, CFD, CFP, CKAP4, FCER1G, FGL2, FPR2, GLIPR1, GNS, LAMTOR2, LTA4H, MGST1, QPCT, RNASE2, |
| G0:0002283 | neutrophil activation involved in immune response | 1.38E-08 | 1.28E-06 | 3.28E-08 | $2.30 \mathrm{E}-07$ | Group7 | [BST1, CD36, CD63, CD68, CD93, CFD, CFP, CKAP4, FCER1G, FGL2, FPR2, GLIPR1, GNS, LAMTOR2, LTA4H, MGST1, QPCT, RNASE2, |
| GO:0043312 | neutrophil degranulation | $1.27 \mathrm{E}-08$ | 1.19E-06 | 3.28E-08 | $2.30 \mathrm{E}-07$ | Group7 | [BST1, CD36, CD63, CD68, CD93, CFD, CFP, CKAP4, FCER1G, FGL2, FPR2, GLIPR1, GNS, LAMTOR2, LTA4H, MGST1, QPCT, RNASE2, SELL, TIMP1, TNFRSF1B] |
| CD14Mono-4 |  |  |  |  |  |  |  |
| G0:0001836 | release of cytochrome c from mitochondria | 2.16E-04 | $5.62 \mathrm{E}-03$ | 2.16E-04 | 1.08E-03 | Group0 | [ARRB2, JUN, LMNA, TNFSF10] |
| 60:0003151 | outiliow tract morphogenesis | 6.05E-03 | $6.05 \mathrm{E}-03$ | 6.05E-03 | 6.05E-03 | Group1 | [CXCR4, JUN, NR3C1] |
| 60:0070373 | negative regulation of ERK1 and ERK2 cascade | 3.57E-04 | $8.20 \mathrm{E}-03$ | $3.57 \mathrm{E}-04$ | $7.13 \mathrm{E}-04$ | Group2 | [DUSP3, DUSP6, GBP1, GSTP1] |
| 60:0071277 | cellular response to calcium ion | 6.05E-03 | 6.05E-03 | 6.05E-03 | 6.05E-03 | Group3 | [ALOX5AP, JUN, JUNB] |
| GO:0050858 | negative regulation of antigen receptormediated signaling pathway | 3.53E-04 | $8.48 \mathrm{E}-03$ | 3.53E-04 | $1.06 \mathrm{E}-03$ | Group4 | [DUSP3, GBP1, LLLRB4] |
| 60:0050860 | negative regulation of $T$ cell receptor signaling pathway | 2.29E-04 | $5.71 \mathrm{E}-03$ | 3.53E-04 | $1.06 \mathrm{E}-03$ | Group4 | [DUSP3, GBP1, LILRB4] |
| GO:0032692 | negative regulation of interleukin-1 production | 4.13E-04 | $9.09 \mathrm{E}-03$ | 3.13E-04 | 1.25E-03 | Group5 | [ARRB2, GSTP1, TNFAlP3] |
| GO:1903556 | negative regulation of tumor necrosis factor superfamily cytokine production | 1.01E-04 | $2.84 \mathrm{E}-03$ | 3.13E-04 | $1.25 \mathrm{E}-03$ | Group5 | [ARRB2, GSTP1, RPSA, TNFAIP3] |
| GO:0032691 | negative regulation of interleukin-1 beta production | 1.70E-04 | $4.58 \mathrm{E}-03$ | 3.13E-04 | 1.25E-03 | Group5 | [ARRB2, GSTP1, TNFAIP3] |
| G0:0032720 | negative regulation of tumor necrosis factor production | 8.97E-05 | $2.60 \mathrm{E}-03$ | 3.13E-04 | $1.25 \mathrm{E}-03$ | Group5 | [ARRB2, GSTP1, RPSA, TNFAIP3] |
| CD16Mono |  |  |  |  |  |  |  |
| 60:0070373 | negative regulation of ERK1 and ERK2 cascade | 5.97E-04 | 5.97E-04 | 5.97E-04 | 5.97E-04 | Group0 | [DUSP6, GBP1, KLF4] |
| 60:0034340 | response to type linterferon | $1.36 \mathrm{E}-06$ | $5.45 \mathrm{E}-06$ | 1.36E-06 | 4.09E-06 | Group1 | [IFI6, IFITT2, IFIT3, IRF1, RSAD2] |
| GO:0071357 | cellular response to type I interferon | 1.02E-06 | $5.10 \mathrm{E}-06$ | $1.36 \mathrm{E}-06$ | 4.09E-06 | Group1 | [IFI6, IFITT2, IFIT3, IRF1, RSAD2] |
| G0:0060337 | type l interferon signaling pathway | 1.02E-06 | $5.10 \mathrm{E}-06$ | $1.36 \mathrm{E}-06$ | $4.09 \mathrm{E}-06$ | Group1 | [IFI6, IFITT2, IFIT3, IRF1, RSAD2] |
| 60:0002920 | regulation of humoral immune response | 3.19E-07 | 2.24E-06 | 1.63E-06 | 3.25E-06 | Group2 | [C1QA, C2, C3AR1, FCGR2A, IGKC, SERPING1] |
| 60:2000257 | regulation of protein activation cascade | 4.02E-06 8 | $\frac{8.04 \mathrm{E}-06}{5}$ | $1.63 \mathrm{E}-06$ $1.63 \mathrm{E}-06$ | $3.25 \mathrm{E}-06$ $3.25 \mathrm{E}-06$ | Group2 <br> Group2 | [C1QA, C2, C3AR1, IGKC, SERPING1] |
| 60:0030449 | regulation of complement activation | $3.59 \mathrm{E}-06$ | $1.08 \mathrm{E}-05$ | 1.63E-06 | 3.25E-06 | Group2 | [C1QA, C2, C3AR1, IGKC, SERPING1] |

Supplemental Table 6. 29 genes differentially expressed in the scRNA-seq data used for cross-validation against bulk RNA-seq data

| Gene | mean_sepsis mean_ARDS | t-test P value |  |
| :--- | :---: | ---: | :---: |
| ATP2B1 | -1.17 | -0.58 | $4.73 \mathrm{E}-08$ |
| C1orf56 | -1.08 | -0.57 | $3.86 \mathrm{E}-06$ |
| C3AR1 | 0.55 | 0.10 | $8.05 \mathrm{E}-03$ |
| CDC42SE1 | -0.45 | -0.33 | $1.18 \mathrm{E}-01$ |
| CLEC4E | -0.22 | -0.56 | $3.44 \mathrm{E}-03$ |
| CLTC | -0.57 | -0.57 | $9.64 \mathrm{E}-01$ |
| CRISPLD2 | -0.24 | -0.07 | $2.03 \mathrm{E}-01$ |
| GBP2 | 1.12 | 0.17 | $4.67 \mathrm{E}-04$ |
| GNG11 | -0.74 | -0.56 | $1.59 \mathrm{E}-02$ |
| GNS | 2.04 | 3.72 | $6.33 \mathrm{E}-14$ |
| HIST1H2AC | 0.17 | -0.57 | $8.00 \mathrm{E}-07$ |
| HSPB1 | 1.02 | -0.54 | $2.48 \mathrm{E}-07$ |
| MAP3K7CL | 0.71 | -0.48 | $8.20 \mathrm{E}-07$ |
| MARCKS | 2.00 | -0.25 | $9.24 \mathrm{E}-15$ |
| MBOAT7 | 0.18 | -0.31 | $3.62 \mathrm{E}-06$ |
| MMD | -0.60 | -0.44 | $1.23 \mathrm{E}-04$ |
| MYL9 | -1.26 | -0.58 | $4.29 \mathrm{E}-08$ |
| NRGN | -0.95 | -0.58 | $4.80 \mathrm{E}-05$ |
| NT5C3A | 0.09 | 0.01 | $6.88 \mathrm{E}-01$ |
| NUP214 | 0.39 | 0.30 | $5.47 \mathrm{E}-01$ |
| PDK4 | -1.08 | 0.01 | $1.51 \mathrm{E}-07$ |
| PDLIM7 | -0.26 | -0.54 | $5.79 \mathrm{E}-03$ |
| PLEK | 1.46 | 0.13 | $4.41 \mathrm{E}-08$ |
| RAB11A | 0.60 | 2.34 | $2.33 \mathrm{E}-21$ |
| RAB11FIP1 | -1.33 | -0.36 | $6.28 \mathrm{E}-10$ |
| SPARC | -1.22 | -0.59 | $1.47 \mathrm{E}-06$ |
| TUBA4A | -0.41 | -0.25 | $5.04 \mathrm{E}-02$ |
| VNN2 | 0.05 | 0.08 | $8.01 \mathrm{E}-01$ |
| YWHAH | 1.21 | 1.87 | $5.01 \mathrm{E}-10$ |

*Expression profile of the 29 genes in GEO datasets. The values were standardized and normalized.
The third column shows $P$ values in $t$ test between the expression levels of the two groups of patients for each gene.
Genes highlighted show similar trends in scRNA-seq and bulk RNA-seq data.

Supplemental Table 7. Description of datasets used for score generation

| GEO dataset | Description | Sample size (used in this analysis) | Platform* |
| :--- | :---: | :---: | :---: |
| GSE89953 | Human Peripheral Blood Monocytes from <br> patients with ARDS at baseline | $\mathrm{N}=26$ ARDS patients | Illumina HumanRef-8 BeadChip |
| GSE46955 | Human Blood Monocytes from gram-negative <br> sepsis patients during sepsis and following <br> their recovery | $\mathrm{N}=8$ patients with sepsis; | Illumina humanRef-8 v2.0 expression |
| beadchip |  |  |  |

* The two datasets have comparable preprocessing and normalization in spite of slightly different platforms.


## Supplemental Table 8. Reagents and Materials

| Reagents | Company | Catalog Number |
| :--- | :--- | :--- |
| Phosphate-buffered saline (PBS) | Fisher Scientific | BW17516Q12 |
| Ficoll Paque PLUS | GE Healthcare | 17144002 |
| Dimethyl Sulfoxide | Sigma-Aldrich | D2650 |
| Fetal Bovine Serum(FBS) | Benchmark | 100106 |
| X-VIVO15 medium | Lonza | 04744 Q |
| RPMI medium | ATCC | $30-2001$ |
| Human AB serum | Fisher Scientific | ICN2938249 |
| 2-mercaptoethanol | Gibco | $21985-023$ |
| Bovine Serum Albumin (BSA) | Gibco | 15260037 |
| Chromium Single Cell 3' Library \& Gel Bead Kit | 10x Genomics | 120267 |
| Chromium Single Cell A Chip Kit, 48 runs | 10x Genomics | 120236 |
| RBC Iysis buffer | BioLegend | 420301 |
| Acid citrate dextrose blood collection tube | Fisher Scientific | $02-684-26$ |
| 50ml Falcon tube | ThermoFisher | 352098 |
| 5ml Falcon staining tube | Fisher Scientific | $14-959-5$ |
| Nalgene Cryo 1C freezing container | ThermoFisher | $5100-0001$ |

